Establishment of NAFLD Cohort and Development of Fibrosis Markers

Establishment of Non-alcoholic Fatty Liver Disease Cohort and Development of Markers to Predict Histologic Progression of Liver Fibrosis

This study is designed for establishment of non-alcoholic fatty liver disease patients cohort to development of markers to predict histologic progression of liver fibrosis.

• Acoustic radiation force impulse elastography and transient elastography
• Liver tissue (frozen tissue, paraffin block)
• Whole blood, Serum
• Fat amount ratio CT (Visceral adipose tissue, Subcutaneous adipose tissue amount)
• Body composition analyzer (InBody scale):Total fat/muscle mass and appendicular skeletal muscle mass
• Pulmonary function test with post-bronchodilator response and DLCo
• EKG, EchoCG, Heart CT (Coronary calcium score), and Pusle wave velocity (AI index, arterial stiffness)
• Brain MRI or CT
• Upper esophagogastroscopy and colonoscopy
• Berlin score questionnaire and Polysomnography

Inclusion Criteria:

• Patients with histologically confirmed fatty liver disease
• Patients with radiologically confirmed fatty liver disease

Exclusion Criteria:

• History of significant alcohol consumption
• Viral hepatitis
• Autoimmune hepatitis
• Metabolic diseases (e.g. hemochromatosis, M. Wilson, alpha 1-antitrypsin deficiency)
• Hepatotoxic medication (e.g. amiodarone)